Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cell therapy targets Epstein-Barr virus in immune-compromised patients Results expected Jun 2027 (estimated)
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…
Phase 1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill takes aim at tough lung cancer mutations
Disease control Recruiting nowThis study tests an experimental oral drug called STX-721 in people with advanced non-small cell lung cancer that has specific EGFR or HER2 gene mutations. The trial has three parts: first finding a safe dose, then confirming the best dose, and finally expanding to more participa…
Phase 1/2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThis phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…
Phase 3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for Drug-Resistant lung cancer: experimental pill enters human trials
Disease control Recruiting nowThis study tests a new oral drug, STX-241, in people with advanced non-small cell lung cancer that has become resistant to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial aims to find the safest…
Phase 1/2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC